Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Anticipated growth for ‘Saudi Arabia Benign Prostatic Hyperplasia Treatment Market’ is significant from 2024 to 2032. The market showed steady growth in 2024 and is expected to continue rising due to ...

Benign prostatic hyperplasia is a common condition, especially in older men. There are a lot of treatments for it, from lifestyle changes to medication and surgery. Your doctor can help you choose ...

VIJAYAWADA: Prashanth Hospital in Vijayawada introduced Resume Water Vapour Therapy for prostate problems, a first in the ...

Alfuzosin alone and alfuzosin-finasteride combination therapy significantly improved symptoms when compared with finasteride alone, as assessed with the International Prostate Symptom Score.

Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...

The treatment of benign prostatic hyperplasia (BPH) that causes lower urinary tract symptoms has advanced enormously since the days when it was a simple choice between no treatment with ...

In the OPD, every day, 5 in 10 men over 60 are complaining of urinary problems and are evaluated for BPH. Thus, an expert has ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

Benign prostatic hyperplasia (BPH), also called prostate gland enlargement, is a common condition that older men can suffer ...